Publications by authors named "Catherine Ellis"

Claim this Profile
I
INDUCE-3: A randomized Phase II/III study of first-line feladilimab plus pembrolizumab in patients with recurrent/metastatic head and neck squamous cell carcinoma.
Danny Rischin, Aaron R Hansen, Ezra E W Cohen, Makoto Tahara, Kevin J Harrington, Catherine Ellis

Clin Cancer Res· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-human phase 1 study of the ICOS agonist feladilimab on patients with advanced solid tumors.
Michele Maio, Victor Moreno, Juan Martin-Liberal, Frans Opdam, Aaron Hansen, Catherine Ellis

J Immunother Cancer· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Indirect treatment comparison of momelotinib vs fedratinib safety in patients with myelofibrosis.
Lucia Masarova, Srdan Verstovsek, Francesca Palandri, Ruben Mesa, Claire Harrison, Catherine Ellis

Future Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Indirect treatment comparisons of momelotinib vs pacritinib safety and anemia outcomes in patients with myelofibrosis.
Lucia Masarova, Srdan Verstovsek, Francesca Palandri, Ruben Mesa, Claire Harrison, Catherine Ellis

Future Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time Without Transfusion Reliance (TWiTR): Integrating Survival Quality Into Myelofibrosis Treatment Strategies Based on the Phase 3 SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM Trials.
Ruben A Mesa, Moshe Talpaz, Flora Mazerolle, Boris Gorsh, Manal M'Hari, Catherine Ellis

EJHaem· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the Effect of Momelotinib on Cardiac Repolarization: A Thorough QT Study.
Georgios Vlasakakis, Yolanda Alvarez, Timothy Hart, Yu Liu Ho, Catherine Ellis

Clin Pharmacol Drug Dev· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longitudinal Assessment of Transfusion Intensity in Patients With JAK Inhibitor-Naive or -Experienced Myelofibrosis Treated With Momelotinib.
Claire N Harrison, Ruben Mesa, Moshe Talpaz, Vikas Gupta, Aaron T Gerds, Catherine Ellis

Clin Lymphoma Myeloma Leuk· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Myelofibrosis symptom assessment form total symptom score version 4.0: measurement properties from the MOMENTUM phase 3 study.
Christina Daskalopoulou, Boris Gorsh, Gerasimos Dumi, Samineh Deheshi, Chad Gwaltney, Catherine Ellis

Qual Life Res· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CITRINO: phase 1 dose escalation study of anti-LAG-3 antibody encelimab alone or in combination with anti-PD-1 dostarlimab in patients with advanced/metastatic solid tumours.
J Randolph Hecht, Jean-Marie Michot, David Bajor, Amita Patnaik, Ki Y Chung, Catherine Ellis

BJC Rep· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anemia in Myelofibrosis: A Focus on Proactive Management and the Role of Momelotinib.
Haifa Kathrin Al-Ali, Andrew T Kuykendall, Catherine E Ellis, Janardhan Sampath, Ruben Mesa

Cancers (Basel)· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Momelotinib versus Continued Ruxolitinib or Best Available Therapy in JAK Inhibitor-Experienced Patients with Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-2.
Claire N Harrison, Alessandro M Vannucchi, Christian Recher, Francesco Passamonti, Aaron T Gerds, Catherine Ellis

Adv Ther· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Momelotinib: Mechanism of action, clinical, and translational science.
Georgios Vlasakakis, Michael T McCabe, Yu Liu Ho, Geraldine Ferron-Brady, Paul Martin, Catherine Ellis

Clin Transl Sci· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Momelotinib vs. ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trial.
Vikas Gupta, Stephen Oh, Timothy Devos, Viviane Dubruille, John Catalano, Catherine Ellis

Leuk Lymphoma· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anemia-related response end points in myelofibrosis clinical trials: current trends and need for renewed consensus.
Barbara J Klencke, Rafe Donahue, Boris Gorsh, Catherine Ellis, Jun Kawashima

Future Oncol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neuroendocrine neoplasms: Consensus on a patient care pathway.
Jessica Hooper, Nikie Jervis, Lucy Morgan, Vivienne Beckett, Philippa Hand, Catherine Bouvier Ellis

J Neuroendocrinol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade.
Sapna Yadavilli, Jeremy D Waight, Sara Brett, Meixia Bi, Tianqian Zhang, Catherine Ellis

Cancer Res Commun· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adolescence as the Context for Understanding Young Mothers' Engagement with Health Promotion: A Phenomenological Exploration.
Catherine Ellis, Peter Sidebotham

Children (Basel)· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Decision-making for the infant sleep environment among families with children considered to be at risk of sudden unexpected death in infancy: a systematic review and qualitative metasynthesis.
Anna Pease, Joanna J Garstang, Catherine Ellis, Debbie Watson, Jenny Ingram

BMJ Paediatr Open· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interventions to Improve Safer Sleep Practices in Families With Children Considered to Be at Increased Risk for Sudden Unexpected Death in Infancy: A Systematic Review.
Catherine Ellis, Anna Pease, Joanna Garstang, Debbie Watson, Peter S Blair

Front Pediatr· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I, First-in-Human Study of GSK2849330, an Anti-HER3 Monoclonal Antibody, in HER3-Expressing Solid Tumors.
Hui K Gan, Michael Millward, Mathilde Jalving, Ignacio Garrido-Laguna, Jason D Lickliter, Catherine Ellis

Oncologist· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improving engagement with services to prevent Sudden Unexpected Death in Infancy (SUDI) in families with children at risk of significant harm: A systematic review of evidence.
Joanna Garstang, Debbie Watson, Anna Pease, Catherine Ellis, Peter S Blair

Child Care Health Dev· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors.
Anthony W Tolcher, Razelle Kurzrock, Vincente Valero, Rene Gonzalez, Rebecca S Heist, Catherine Ellis

Cancer Chemother Pharmacol· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The benefit of evolving multidisciplinary care in ALS: a diagnostic cohort survival comparison.
Sarah Martin, Emma Trevor-Jones, Sabyha Khan, Keelan Shaw, Deepti Marchment, Catherine E Ellis

Amyotroph Lateral Scler Frontotemporal Degener· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of serum HER2, TIMP-1, and CAIX on outcome for HER2+ metastatic breast cancer patients: CCTG MA.31 (lapatinib vs. trastuzumab).
Diep Ho, Jessica Huang, Judith-Anne W Chapman, Kim Leitzel, Suhail M Ali, Catherine E Ellis

Breast Cancer Res Treat· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis